首页> 外国专利> NINGALIN B ANALOGS EMPLOYABLE FOR REVERSING MULTIDRUG RESISTANCE

NINGALIN B ANALOGS EMPLOYABLE FOR REVERSING MULTIDRUG RESISTANCE

机译:可用于逆转多药耐药性的宁纳林B模拟

摘要

Anlogs of ningalin B lacking inherent cytotoxic activity may be employed to reverse multi-drug resistant (MDR) phenotype and to resensitize transformed cells, including a human colon cancer cell line (HCT116/VM46), with respect to a variety of cytotoxic agents, e.g., vinblastine and doxorubicin. In many instances, resensitization is achieved at lower doses than the prototypical agent verapamil. Total synthesis of ningalin B and its analogs was achieved using a concise, efficient approach based on a heterocyclic azadiene Diels-Alder strategy (1,2,4,5-tetrazine-1,2-diazine-pyrrole) ideally suited for construction of the densely functionalized pyrrole core found in the natural product is detailed.
机译:缺乏固有细胞毒性活性的宁那林B的类似物可用于逆转多重耐药性(MDR)表型并使包括人类结肠癌细胞系(HCT116 / VM46)在内的转化细胞重新敏感,例如多种细胞毒性剂,长春碱和阿霉素。在许多情况下,以比原型药物维拉帕米更低的剂量实现了再敏化。宁格灵B及其类似物的全合成是使用一种简捷有效的方法实现的,该方法基于杂环氮杂二烯Diels-Alder策略(1,2,4,5-四嗪-> 1,2-二嗪->吡咯),非常适合于构建详细介绍了在天然产物中发现的稠密官能化吡咯核心。

著录项

  • 公开/公告号EP1263723A4

    专利类型

  • 公开/公告日2004-12-29

    原文格式PDF

  • 申请/专利权人 THE SCRIPPS RESEARCH INSTITUTE;

    申请/专利号EP20010913273

  • 发明设计人 BOGER DALE L.;

    申请日2001-03-01

  • 分类号C07D207/00;C07D223/14;C07D237/00;C07D491/12;A61K31/40;A61K31/50;A61K31/55;

  • 国家 EP

  • 入库时间 2022-08-21 22:11:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号